BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12826842)

  • 1. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test.
    Paniccia R; Fedi S; Carbonetto F; Noferi D; Conti P; Bandinelli B; Giusti B; Evangelisti L; Pretelli P; Palmarini MF; Abbate R; Prisco D
    Anesthesiology; 2003 Jul; 99(1):54-9. PubMed ID: 12826842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.
    Dirkmann D; Nagy E; Britten MW; Peters J
    BMC Anesthesiol; 2019 Sep; 19(1):174. PubMed ID: 31492108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Point-of-Care ACT Coagulometers and Anti-Xa Activity During Cardiopulmonary Bypass.
    Falter F; MacDonald S; Matthews C; Kemna E; Cañameres J; Besser M
    J Cardiothorac Vasc Anesth; 2020 Nov; 34(11):2921-2927. PubMed ID: 32620484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Heparin Anticoagulation Measured Using i-STAT and Hemochron Activated Clotting Time.
    Maslow A; Chambers A; Cheves T; Sweeney J
    J Cardiothorac Vasc Anesth; 2018 Aug; 32(4):1603-1608. PubMed ID: 29503117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
    Chia S; Van Cott EM; Raffel OC; Jang IK
    Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative Monitoring of Heparin: Comparison of Activated Coagulation Time and Whole Blood Heparin Measurements by Different Point-of-Care Devices with Heparin Concentration by Laboratory-Performed Plasma Anti-Xa Assay.
    Thompson TZ; Kunak RL; Savage NM; Agarwal S; Chazelle J; Singh G
    Lab Med; 2019 Oct; 50(4):348-356. PubMed ID: 31053856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery.
    Niles SD; Sutton RG; Ploessl J; Pennell B
    J Extra Corpor Technol; 1995 Dec; 27(4):197-200. PubMed ID: 10172651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition from Hemochron Response to Hemochron Signature Elite Activated Clotting Time Devices in a Congenital Cardiac Surgery Practice.
    Matte GS; Howe RJ; Ibla J; Emani S; Emani SM
    J Extra Corpor Technol; 2019 Dec; 51(4):221-226. PubMed ID: 31915405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
    Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.
    Welsby IJ; McDonnell E; El-Moalem H; Stafford-Smith M; Toffaletti JG
    J Clin Monit Comput; 2002 Jul; 17(5):287-92. PubMed ID: 12546261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedside testing with the new CoaguChek Pro activated clotting time assay in dialysis.
    Bommer J; Schwab M
    Artif Organs; 2002 Apr; 26(4):387-90. PubMed ID: 11952512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR).
    Tremey B; Szekely B; Schlumberger S; François D; Liu N; Sievert K; Fischler M
    Br J Anaesth; 2006 Oct; 97(4):453-9. PubMed ID: 16873382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
    Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
    Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time.
    Raymond PD; Ray MJ; Callen SN; Marsh NA
    Perfusion; 2003 Sep; 18(5):269-76. PubMed ID: 14604242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.